Daily Financial UpdateMarket Pulse: Crypto storms into a new record as Bitcoin blasts past old ceilings, dragging risk appetite to another level while biotech names snap up gains on fresh wins. Key Movers: Bitcoin’s whirlwind short squeeze (TheStreet), Nurix Therapeutics’ earnings romp, and Regeneron’s FDA go-ahead are fueling volatility across asset classes. Macro & Politics: Washington’s steep tariffs on Canadian imports are rattling supply chains and driving investors toward bonded warehouse plays, even as the Supreme Court grants retailers new standing in vaping disputes. What’s Next: Eyes on any tariff clarifications and FDA updates before markets open—they could fan fresh momentum or trigger a snapback. Market CommentaryEveryone’s so hyped on crypto’s meteoric surge and biotech breakouts that they’re ignoring the tariff fallout strangling Main Street. Take the century-old Michigan clock maker shuttering operations under Washington’s import levies (NBC News): that’s what a misguided trade policy looks like when theory meets real-world pain. Markets may chase safe-haven plays, but broader small-business casualties are the real red flag—bullshit when they say trade wars only hit the other guy. Jim Cramer’s “sliding stocks to buy at a bargain” blitz (TheStreet) could be a neat playbook—except we’re staring at a U.S. debt outlook that Fortune says now rivals the student loan crisis. Buying the dip in consumer names makes sense until the debt machinery gobbles up future growth. It’s one hell of a market when bargain hunters lock horns with the ultimate fiscal reckoning. Here’s the play: stash weight in FDA-friendly biotech stories—Nurix wasn’t the exception, it was the rule, and Kuick Research’s bispecific ADC forecast screams upside. For the crypto crowd, lean into momentum plays like INJ but pare back if ADA’s 23% ramp starts to fizzle (Ambcrypto). Keep chips on both tables, but don’t pretend risk turned docile overnight. 📈 Breaking Financial NewsTheStreetJim Cramer shares sliding stocks to buy at a bargainThe television personality wants to sound the alarm about all four of these brands. MarcaClub World Cup 2025 Prize: How much money will the winner of the tournament between Chelsea and PSG earn?The 2025 Club World Cup final is here, and the football world comes to a standstill to witness a clash of titans: Chelsea vs PSG This Sunday, July 13, the MetLife Stadium in New Je Ambcrypto.comDecoding Injective’s breakout: Can INJ bulls target $14 and beyond?INJ’s breakout triggers bullish momentum, backed by whales, rising funding, and heating futures. NBC NewsTime runs out for nearly century-old Michigan clock company due to tariffs, other factorsZEELAND, Mich. (AP) — A Michigan clock company that has helped people keep time for 99 years says it’s going out of business due to tariffs and other economic conditions TheStreetShort sellers face market's wrath as $700M gets liquidated in minutesMore than $560 million in crypto positions—mostly shorts—were liquidated in just one hour, with Bitcoin alone accounting for $425 million. A textbook short... The "Lazy" Way to Make Money in the MarketDiscover how millionaire trader Tim Sykes turns his weekends into a cash machine with a single trade on Friday afternoon. Imagine waking up Monday morning thousands of dollars richer... without lifting a finger all weekend! Learn More →🔍 Market Analysis & InsightsThe Washington PostWhy Wall Street is brushing off Trump’s escalating tariff threatsPresident Donald Trump’s escalating tariff threats have not deterred Wall Street, with the stock market continuing to rise despite trade policy uncertainty. newsBTCBitcoin Bulls In Cloud 9? Analyst Identifies Where Risk LiesAfter a near-excellent start to the month of July, Bitcoin has performed even more impressively over the past few days. The premier cryptocurrency, after a brief period of sideways momentum earlier this week, has attained a new all-time-high valuation at a pr… GlobeNewswireBispecific Antibody Drug Conjugates Clinical Trials FDA Approval Market Trends ReportFirst Bispecific Antibody Drug Conjugates Commercial Approval Expected By 2029 Says Kuick Research First Bispecific Antibody Drug Conjugates Commercial Approval Expected By 2029 Says Kuick Research Ambcrypto.comCardano – Here’s why ADA’s 23% rally could call for caution!ADA might drop soon as it enters a new market phase. SiliconANGLE NewsAI ecosystems in full swing at RAISE SummitI’ve been to several AI-focused conferences since I moved to Europe in 2023. Most of them suffer from trying too hard – driving the hype around AI beyond its current utility. This week’s RAISE Summit in Paris was a refreshing exception. I spoke with several e… This Tiny AI stock is the "trade of the year"Huge AI Opportunity: This tiny AI stock could make you 75X richer in 2025! Learn More →💰 Investment OpportunitiesYahoo EntertainmentMcKesson Corporation (MCK): If It Was Down, I’d Say “Fill Her Up,” Says Jim CramerWe recently published Jim Cramer’s Fresh 14 Stocks & Thoughts About Market Performance. McKesson Corporation (NYSE:MCK) is one of the stocks Jim Cramer... WiredHate Prime Day? Shop These Small Biz Sales InsteadFeeling anti-Amazon? These small businesses have sales you can shop right now before the week of sales ends. FortuneThe U.S. debt outlook is so dire it now resembles the student loan crisis, former White House economic adviser says"I, like many other longtime doves, am joining the hawks, because our nation’s budget math just got a lot more dangerous." Yahoo EntertainmentProcessa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio ProgressProcessa Pharmaceuticals, Inc. (NASDAQ:PCSA) is among the fundamentally strong penny stocks to invest in. Analysts at H.C. Wainwright have reiterated their... LivemintWorst Spate of Downgrades Since 2021 Signals PainCredit rating downgrades are becoming more frequent, the latest sign that companies are starting to perform worse and raising fresh questions about whether corporate debt valuations should be as high as they are. Amazon Spending $10 Billion on THIS...Jeff Bezos is on a mission to dominate the AI revolution. And he's not afraid to spend BIG. Amazon is pouring billions into a little-known technology most investors are ignoring. But expert Jeff Brown thinks it could be the biggest opportunity of the decade. Learn More → | 